Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of < sup > 225 < /sup > Ac-J591

CONCLUSION: To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.PMID:37922438 | DOI:10.1200/JCO.23.00573

Source: Clinical Prostate Cancer - November 3, 2023 Category: Cancer & Oncology Authors: Scott T Tagawa Charlene Thomas A Oliver Sartor Michael Sun Judith Stangl-Kremser Mahelia Bissassar Shankar Vallabhajosula Sandra Huicochea Castellanos Jones T Nauseef Cora N Sternberg Ana Molina Karla Ballman David M Nanus Joseph Osborne Neil H Bander Source Type: research